128 related articles for article (PubMed ID: 11673814)
1. Antiviral potency of HAART regimens and clinical success are not strictly coupled in real life conditions: evidence from the MASTER-1 study.
Carosi G; Castelli F; Suter F; Maggiolo F; Orani AM; Pan A; Andreoni M; Vigevani GM; Maserati R; Mazzotta F; Tinelli C;
HIV Clin Trials; 2001; 2(5):399-407. PubMed ID: 11673814
[TBL] [Abstract][Full Text] [Related]
2. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).
Cohen Stuart JW; Schuurman R; Burger DM; Koopmans PP; Sprenger HG; Juttmann JR; Richter C; Meenhorst PL; Hoetelmans RM; Kroon FP; Bravenboer B; Hamann D; Boucher CA; Borleffs JC
AIDS; 1999 May; 13(7):F53-8. PubMed ID: 10357371
[TBL] [Abstract][Full Text] [Related]
4. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.
Carr A; Chuah J; Hudson J; French M; Hoy J; Law M; Sayer D; Emery S; Cooper DA
AIDS; 2000 Jun; 14(9):1171-80. PubMed ID: 10894281
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection.
d'Arminio Monforte A; Testa L; Adorni F; Chiesa E; Bini T; Moscatelli GC; Abeli C; Rusconi S; Sollima S; Balotta C; Musicco M; Galli M; Moroni M
AIDS; 1998 Sep; 12(13):1631-7. PubMed ID: 9764782
[TBL] [Abstract][Full Text] [Related]
6. Three-year effectiveness of highly active antiretroviral treatment in the Luxembourg HIV cohort.
Servais J; Schmit JC; Arendt V; Lambert C; Staub T; Robert I; Fontaine E; Plesséria JM; Burgy C; Kirpach P; Schneider F; Hemmer R
HIV Clin Trials; 2000; 1(2):17-24. PubMed ID: 11590494
[TBL] [Abstract][Full Text] [Related]
7. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
Schapiro JM; Winters MA; Lawrence J; Merigan TC
AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir.
Kirk O; Mocroft A; Pradier C; Bruun JN; Hemmer R; Clotet B; Miller V; Viard JP; Phillips AN; Lundgren JD;
AIDS; 2001 May; 15(8):999-1008. PubMed ID: 11399982
[TBL] [Abstract][Full Text] [Related]
9. Use of the protease inhibitor saquinavir hard gel in human immunodeficiency virus-infected patients in the early period of highly active antiretroviral therapy: does it affect long-term treatment outcome?
Jensen-Fangel S; Pedersen C; Nielsen H; Tauris P; Møller A; Sørensen HT; Obel N
Scand J Infect Dis; 2003; 35(10):743-9. PubMed ID: 14606614
[TBL] [Abstract][Full Text] [Related]
10. The use of efavirenz as a part of late rescue antiretroviral treatment.
Manfredi R; Rizzo E; Calza L; Chiodo F
HIV Clin Trials; 2001; 2(5):413-20. PubMed ID: 11673816
[TBL] [Abstract][Full Text] [Related]
11. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients.
Casado JL; Perez-Elías MJ; Antela A; Sabido R; Martí-Belda P; Dronda F; Blazquez J; Quereda C
AIDS; 1998 Jul; 12(11):F131-5. PubMed ID: 9708403
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor.
Grabar S; Pradier C; Le Corfec E; Lancar R; Allavena C; Bentata M; Berlureau P; Dupont C; Fabbro-Peray P; Poizot-Martin I; Costagliola D
AIDS; 2000 Jan; 14(2):141-9. PubMed ID: 10708284
[TBL] [Abstract][Full Text] [Related]
13. The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study.
Jensen-Fangel S; Kirk O; Blaxhult A; Gerstoft J; Pedersen C; Black FT; Lundgren JD; Obel N
HIV Clin Trials; 2001; 2(2):122-7. PubMed ID: 11590520
[TBL] [Abstract][Full Text] [Related]
14. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
[TBL] [Abstract][Full Text] [Related]
15. The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study.
Mocroft A; Phillips AN; Miller V; Gatell J; van Lunzen J; Parkin JM; Weber R; Roge B; Lazzarin A; Lundgren JD;
AIDS; 2001 Jan; 15(2):201-9. PubMed ID: 11216928
[TBL] [Abstract][Full Text] [Related]
16. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team.
Mitsuyasu RT; Skolnik PR; Cohen SR; Conway B; Gill MJ; Jensen PC; Pulvirenti JJ; Slater LN; Schooley RT; Thompson MA; Torres RA; Tsoukas CM
AIDS; 1998 Jul; 12(11):F103-9. PubMed ID: 9708399
[TBL] [Abstract][Full Text] [Related]
17. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
18. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
19. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.
d'Arminio Monforte A; Lepri AC; Rezza G; Pezzotti P; Antinori A; Phillips AN; Angarano G; Colangeli V; De Luca A; Ippolito G; Caggese L; Soscia F; Filice G; Gritti F; Narciso P; Tirelli U; Moroni M
AIDS; 2000 Mar; 14(5):499-507. PubMed ID: 10780712
[TBL] [Abstract][Full Text] [Related]
20. [A randomized clinical trial to compare the effectiveness of indinavir, ritonavir and saquinavir].
Teira R; Cámara MM; Escobar A; Muñoz P; López de Munain J; Santamaría JM
Med Clin (Barc); 2003 Oct; 121(14):532-4. PubMed ID: 14599408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]